ArticleWorld journal of oncology2026
Transcription Factor MAX Regulates Liver Cancer Cell Growth, Migration, Invasion, and Epithelial-Mesenchymal Transition by Promoting SF3A3 Expression.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The regulatory relationship between transcription factor MAX and splicing factor SF3A3 in hepatocellular carcinoma (HCC) is unknown. We investigated whether MAX directly regulates SF3A3 and their functional role in HCC progression. Methods: MAX and SF3A3 expression were analyzed in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-HCC) dataset (UALCAN, GEPIA) and validated in 33 paired HCC and adjacent non-tumor tissues by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Expression and prognostic significance were assessed across cancer stages, grades, and nodal status. Functional roles were evaluated in Hep3B (high expression) and PLC/PRF/5 (low expression) cells using shRNA-mediated knockdown and overexpression, respectively. Cell proliferation (cell counting kit-8, colony formation), migration (wound healing, Transwell), invasion (Matrigel Transwell), and epithelial-mesenchymal transition (EMT) (Western blot for E-cadherin, N-cadherin, and vimentin) were assessed. Mechanistic studies included chromatin immunoprecipitation (ChIP)-quantitative polymerase chain reaction (qPCR), luciferase reporter assays with site-directed mutagenesis, and Myc inhibition. Results: MAX and SF3A3 were overexpressed in HCC tissues compared to normal liver, and high expression was correlated with reduced patient survival, advanced cancer stage, higher tumor grade, and nodal metastasis. A significant positive correlation between MAX and SF3A3 expression was observed. Functional assays demonstrated that MAX or SF3A3 overexpression promoted HCC cell proliferation, migration, invasion, and EMT, while knockdown suppressed these phenotypes. MAX directly bound the SF3A3 promoter (P3 E-box) and activated its transcription in a Myc-dependent manner. Overexpression of MAX or SF3A3 promoted malignant phenotypes, while SF3A3 knockdown reversed MAX-driven oncogenic effects Conclusion: This study establishes a novel MAX-SF3A3 regulatory axis in which MAX directly binds the SF3A3 promoter and activates its transcription in a Myc-dependent manner, driving HCC cell proliferation, migration, invasion, EMT, and tumor growth. Targeting the MAX-SF3A3 axis represents a potential therapeutic strategy for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.